MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Calcitriol 1 mcg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 002 471v2

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Calcitriol 0.1 mg/mL Stock Solution †	0.20	mL				
Polysorbate 80, NF	0.08	g				
Ascorbic Acid, USP	0.10	g				
Sodium Chloride, USP	0.16	g				
Sterile Water for Injection, USP	15.0	mL				
Sterile Water for Injection, USP	q.s. to 20.0	mL				
Sodium Hydroxide 1N Solution	As required					
† **Calcitriol 0.1 mg/mL Stock Solution**						
Calcitriol (Anhydrous), USP	0.050	g				
Alcohol (95%), USP	500.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive *(protect from light whenever possible):* *Calcitriol, Ascorbic Acid, Polysorbate 80*

Hygroscopic *(protect from moisture whenever possible):* *Polysorbate 80*

Oxygen Sensitive *(protect from air whenever possible):* *Ascorbic Acid, Polysorbate 80*

Heat Sensitive *(protect from heat whenever possible):* *Calcitriol*

Air Sensitive *(protect from heat whenever possible):* *Calcitriol*

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Calcitriol 1 mcg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 002 471v2

SPECIAL PREPARATORY CONSIDERATIONS (CONTINUED)

Suggested Preparatory Guidelines

☐ Non-Sterile Preparation ■ Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **15 to 20%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797* and *USP 800* when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Compounder needs to verify as per USP, if every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

All required personal protective equipment (sterile and hazardous if applicable), such as but not limited to, gowns, aprons, sleeves, gloves both inner and outer if applicable, shoe covers, hairnet, head cap, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFIs) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Calcitriol 1 mcg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 002 471v2

SUGGESTED PREPARATION (for 20 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Calcitriol 0.1 mg/mL Stock Solution § †	0.20	mL			
Polysorbate 80, NF §	0.08	g			
Ascorbic Acid, USP §	0.10	g			
Sodium Chloride, USP §	0.16	g			
Sterile Water for Injection, USP §	15.0	mL			
Sterile Water for Injection, USP §	q.s. to 20.0	mL			
Sodium Hydroxide 1N Solution §	As required				
† **Calcitriol 0.1 mg/mL Stock Solution**					
Calcitriol (Anhydrous), USP §	0.050	g	---	--	
Alcohol (95%), USP §	500.0	mL	---	---	

* Takes into account increased batch size conversions and density conversions, if required.
§ Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. **Equipment sterilization:**

   Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

2. † **Calcitriol 0.1 mg/mL Stock Solution preparation:**

   A. Triturate the Calcitriol (Anhydrous) to form a fine, homogeneous powder.

   B. Incrementally add the fine, homogeneous powder (Step 2A) to the Alcohol (95%).

   Specifications: Continuously mix until all solid particles have completely dissolved.

   End result: Homogeneous liquid-like solution.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Calcitriol 1 mcg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 002 471v2

3. **Powder preparation:**

A. Combine and mix the following ingredients together to form a fine, homogeneous powder blend:

-Ascorbic Acid
-Sodium Chloride

4. **Powder-liquid preparation:**

A. In the given order, sequentially add the following ingredients to the Sterile Water for Injection (15.0 mL *plus* processing error adjustments):

-Calcitriol 0.1 mg/mL Stock Solution (0.20 mL *plus* processing error adjustments)
-Polysorbate 80

Specifications: Continuously mix.

End result: Homogeneous liquid-like solution.

Note: Add the next ingredient, once the previous one has been completely added and dissolved.

5. **Phase integration:**

A. Incrementally add the fine, homogeneous powder blend (Step 3A) to the homogeneous liquid-like solution (Step 4A).

Specifications: Continuously mix until all solid particles have completely dissolved.

End result: Homogeneous liquid-like solution.

6. **pH testing:**

A. Draw an appropriate amount of the mixture (Step 5A).

B. Test the pH of the sample. It should lie between 6.8 and 7.2.

C. If the pH < 6.8, carefully add in a dropwise manner the Sodium Hydroxide 1N Solution to the mixture:

1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 1N Solution to the mixture.
2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 1N Solution.
3. Re-test the pH.
4. Continue to add the Sodium Hydroxide 1N Solution until the pH of 6.8 to 7.2 is obtained.

IMPORTANT: Do not allow the pH to rise above 7.2.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Calcitriol 1 mcg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 002 471v2

7.	**Filling to volume:** A. Add additional Sterile Water for Injection to the above mixture to fill to the required batch size (20.0 mL *plus* processing error adjustments). Specifications: Continuously mix. End result: Homogeneous liquid-like solution.
8.	**Filtering and transferring:** Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.
9.	**Filter integrity test:** Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
10.	**Terminal Sterilization:** In relation to the chemical composition of the formulation, final packaging, etc., select and validate an end-stage sterilization method and follow the manufacturer's specification.
11.	**Sterility and Endotoxin testing:** Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Calcitriol 1 mcg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 002 471v2

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		24 hours controlled room temperature, 3 days refrigerated, or 45 days frozen, as per USP 797. BUD based on successful endotoxin test result.	Packaging Requirements		Sterile, light-resistant unit-dose injection vials (1 mL)
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.		7	Discard in the presence of particulate matter.
	2	Keep out of reach of children.		8	Discard container after use.
	3	Protect from light.		9	Keep at controlled room temperature (20°C – 25°C), refrigerated (2°C – 8°C) or frozen (-25°C to -10°C).
	4	Do not use if discolored.		10	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	5	May impair mental and or physical ability. Use care when operating a car or machinery.		11	Equilibrate to room temperature before use.
	6	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.			
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.				
Patient Instructions	Contact your pharmacist in the event of adverse reactions.				

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Calcitriol 1 mcg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 002 471v2

REFERENCES

1. Polyoxyethylene Sorbitan Fatty Acid Esters. In: Rowe RC. *Handbook of Pharmaceutical Excipients, 4th Edition*. American Pharmaceutical Association; 2003: 479.
2. Calcitriol (Monograph). In: O'Neil MJ. *The Merck Index 13th Edition*. Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 1644.
3. USP <797> Pharmaceutical Compounding – Sterile Preparations. US Pharmacopeial Convention, Inc. *United States Pharmacopeia XXVIII / National Formulary 23.* Rockville, MD. 2004: 2461.
4. Ascorbic Acid. In: Trissel LA. *Trissel's Stability of Compounded Formulations, 2nd Edition.* American Pharmaceutical Association; 2000: 30.
5. Tonicity, Osmoticity, Osmolality and Osmolarity. In: Gennaro AR, ed. *Remington: The Science and Practice of Pharmacy, 20th Edition.* Baltimore, MD: Lippincott Williams & Wilkins; 2000: 246.